tetano
Editor, Senior Moderator
Sci Rep
. 2020 Aug 24;10(1):14122.
doi: 10.1038/s41598-020-70996-x.
Ten years of vaccinovigilance in Italy: an overview of the pharmacovigilance data from 2008 to 2017
F Moretti[SUP] 1 [/SUP], L Gonella[SUP] 2 [/SUP], S Gironi[SUP] 1 [/SUP], A R Marra[SUP] 3 [/SUP], C Santuccio[SUP] 3 [/SUP], P Felicetti[SUP] 3 [/SUP], F Petronzelli[SUP] 3 [/SUP], P Marchione[SUP] 3 [/SUP], S A Barnaba[SUP] 4 [/SUP], A Poli[SUP] 1 [/SUP], G Zanoni[SUP] 5 [/SUP], U Moretti[SUP] 6 [/SUP]
Affiliations
Abstract
Reporting and analysis of Adverse Events Following Immunization (AEFIs) are the cornerstones of vaccine safety surveillance prompting causality assessment and signal detection. This paper describes the impact of the Italian Pharmacovigilance System of vaccines over a 10-year period (2008-2017). The reporting rate (RR) per all distributed dose was calculated. Serious AEFIs and causality assessments for fatal cases were described. The main results from signal detection were reported. During the study period, 46,430 AEFIs were reported with an overall RR of 17.2 per 100,000 distributed doses. Italy showed the highest number of reports among European countries. Only 4.4% of the reports came from citizens. Of the total, 12.7% were classified as serious with a RR over the study period of 2.20 per 100,000 distributed doses. They were mainly related to hyperpyrexia and usually had a positive outcome. Fatal outcomes were reported in 0.3% of the cases and were primarily associated with the influenza vaccine in elderly patients. None of these outcomes had a consistent causal association with the vaccination. Febrile convulsions by the measles, mumps, rubella and varicella vaccines and intussusception by the rotavirus vaccine were among the highlighted signals. The reporting rate and the analysis of serious events from 10 years support the good risk/benefit profiles of vaccines.
. 2020 Aug 24;10(1):14122.
doi: 10.1038/s41598-020-70996-x.
Ten years of vaccinovigilance in Italy: an overview of the pharmacovigilance data from 2008 to 2017
F Moretti[SUP] 1 [/SUP], L Gonella[SUP] 2 [/SUP], S Gironi[SUP] 1 [/SUP], A R Marra[SUP] 3 [/SUP], C Santuccio[SUP] 3 [/SUP], P Felicetti[SUP] 3 [/SUP], F Petronzelli[SUP] 3 [/SUP], P Marchione[SUP] 3 [/SUP], S A Barnaba[SUP] 4 [/SUP], A Poli[SUP] 1 [/SUP], G Zanoni[SUP] 5 [/SUP], U Moretti[SUP] 6 [/SUP]
Affiliations
- PMID: 32839511
- DOI: 10.1038/s41598-020-70996-x
Abstract
Reporting and analysis of Adverse Events Following Immunization (AEFIs) are the cornerstones of vaccine safety surveillance prompting causality assessment and signal detection. This paper describes the impact of the Italian Pharmacovigilance System of vaccines over a 10-year period (2008-2017). The reporting rate (RR) per all distributed dose was calculated. Serious AEFIs and causality assessments for fatal cases were described. The main results from signal detection were reported. During the study period, 46,430 AEFIs were reported with an overall RR of 17.2 per 100,000 distributed doses. Italy showed the highest number of reports among European countries. Only 4.4% of the reports came from citizens. Of the total, 12.7% were classified as serious with a RR over the study period of 2.20 per 100,000 distributed doses. They were mainly related to hyperpyrexia and usually had a positive outcome. Fatal outcomes were reported in 0.3% of the cases and were primarily associated with the influenza vaccine in elderly patients. None of these outcomes had a consistent causal association with the vaccination. Febrile convulsions by the measles, mumps, rubella and varicella vaccines and intussusception by the rotavirus vaccine were among the highlighted signals. The reporting rate and the analysis of serious events from 10 years support the good risk/benefit profiles of vaccines.